Company intelligence / Profile preview

Epiminder

Melbourne, Victoria, Australia

Ownership: Private
Employees: ~20
Development stage: Other

Overview

The Minder implantable continuous EEG monitoring system (iCEM) received FDA De Novo marketing authorization in 2025 following successful UMPIRE clinical trials, which demonstrated safety, equivalence to scalp EEG, and continuous five-year data capture in study participants. Minder enables unprecedented long-term brain monitoring for effective seizure diagnosis, medication adjustment, and management in epilepsy patients, with close to 90% of study participants benefiting from actionable clinical insights.

Therapeutic areas: Neurology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Bionics InstituteCochlearUniversity of MelbourneSt Vincent’s Hospital MelbourneSeer Medical

Beyond the preview

Go deeper on Epiminder.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epiminder.

Explore the full profile